Macquarie Group LTD Allakos Inc. Transaction History

Macquarie Group LTD

$85.1 Billion
Q2 2024

A detailed history of Macquarie Group LTD transactions in Allakos Inc. stock. As of the latest transaction made, Macquarie Group LTD holds 3,422 shares of ALLK stock, worth $2,190. This represents 0.0% of its overall portfolio holdings.

Number of Shares

3,422

Holding current value

$2,190

% of portfolio

0.0%

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 09, 2024	BUY	$1.0 - $1.45 $3,422 - $4,961	3,422 New	3,422 $3,000
Q2 2022 Aug 15, 2022	SELL	$2.6 - $6.14 $3,562 - $8,411	-1,370 Closed	0 $0
Q4 2021 Feb 11, 2022	SELL	$8.55 - $111.89 $7,156 - $93,651	-837 Reduced 37.92%	1,370 $13,000
Q3 2021 Nov 12, 2021	SELL	$76.53 - $110.43 $15,382 - $22,196	-201 Reduced 8.35%	2,207 $234,000
Q2 2021 Aug 13, 2021	SELL	$85.37 - $114.1 $55,319 - $73,936	-648 Reduced 21.2%	2,408 $206,000
Q1 2021 May 14, 2021	BUY	$109.73 - $153.66 $23,921 - $33,497	218 Added 7.68%	3,056 $350,000
Q4 2020 Feb 16, 2021	BUY	$79.58 - $152.45 $125,656 - $240,718	1,579 Added 125.42%	2,838 $397,000
Q2 2020 Aug 11, 2020	SELL	$44.04 - $80.69 $27,348 - $50,108	-621 Reduced 33.03%	1,259 $90,000
Q1 2020 May 15, 2020	BUY	$44.49 - $93.39 $83,641 - $175,573	1,880 New	1,880 $84,000

Others Institutions Holding ALLK

# of Institutions

104

Shares Held

70.7M

Call Options Held

43.8K

Put Options Held

1.4K

Bvf Inc San Francisco, CA

16.6M
Shares

$10.6 Million
0.51% of portfolio
Nea Management Company, LLC Timonium, MD

6.15M
Shares

$3.93 Million
0.58% of portfolio
Deep Track Capital, LP Greenwich, CT

5M
Shares

$3.2 Million
0.16% of portfolio
Vanguard Group Inc Valley Forge, PA

3.51M
Shares

$2.25 Million
0.0% of portfolio
Israel Englander Millennium Management LLC | New York, Ny

3.42M
Shares

$2.19 Million
0.0% of portfolio

View Full List

About Allakos Inc.

Ticker ALLK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,726,096
Market Cap $54.2M
Description
Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and...

More about ALLK

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Macquarie Group LTD, based on Form 13F filings with the SEC.

News

Stay updated on Macquarie Group LTD with notifications on news.

Account